Liquidia presents YUTREPIA data at PHA 2026 conference
Liquidia Corporation will present four posters at the PHA 2026 conference, featuring data from its ASCENT study on YUTREPIA (treprostinil) inhalation powder. The presentations will cover patient-reported cough outcomes in PH-ILD patients, caregiver mental health burdens, and pharmacist roles in PH care teams. The posters will be available on Liquidia's website after the conference.
*this image is generated using AI for illustrative purposes only.
Liquidia Corporation will present four posters at the PHA 2026 International PH Conference and Scientific Sessions in Dallas, showcasing data from its ASCENT study on YUTREPIA (treprostinil) inhalation powder. The presentations, scheduled for June 11-14, will highlight patient-reported cough outcomes in pulmonary hypertension associated with interstitial lung disease (PH-ILD) over 24 weeks of treatment. The company will also share new analyses on the role of pharmacists in PH care teams and the mental health challenges faced by caregivers of PH patients.
Dr. Rajeev Saggar, Chief Medical Officer of Liquidia, emphasized the company's commitment to the pulmonary hypertension community. "This work reflects our dedication to understanding patient experiences, caregiver burdens, and the support provided by care teams," he said. The posters will be displayed from 4 to 5 p.m. CDT on June 11 in the exhibition hall, with digital copies available on Liquidia's website post-presentation.
Key Poster Presentations
The four posters cover a range of topics, including new data from the ASCENT study and encore presentations of previously reported findings. Below is a summary of the posters:
| Poster Number | Title | Focus Area |
|---|---|---|
| #1014 | Hearing from Patients: Self-Reported Cough Outcomes During Treatment with YUTREPIA in the ASCENT Trial | Patient-reported cough outcomes in PH-ILD |
| #1055 | The Invisible Burden: Mental Health Challenges Facing Caregivers of Patients with Pulmonary Hypertension | Caregiver mental health burden |
| #1072 | The PHriendly Neighborhood Pharmacist: Mapping the Pharmacist's Role in Pulmonary Hypertension Care Teams | Pharmacist role in PH care |
| #1060 | A Continued ASCENT to Week 24: Safety and Exploratory Efficacy Data on LIQ861 Dry Powder Inhaled Treprostinil in PH-ILD Patients | Safety and efficacy data (encore) |
About YUTREPIA
YUTREPIA is an inhaled dry-powder formulation of treprostinil, delivered via a palm-sized device designed for low-effort use. It is indicated for improving exercise ability in patients with pulmonary arterial hypertension (PAH) and PH-ILD. The drug was developed using Liquidia's proprietary PRINT technology, which ensures precise and uniform particle size for enhanced lung deposition. YUTREPIA was previously known as LIQ861 during investigational studies.
How will the new 24-week cough outcome data influence regulatory approval timelines for YUTREPIA in PH-ILD?
What strategies will Liquidia employ to differentiate YUTREPIA from existing inhaled treprostinil therapies in the competitive PAH market?
Could the caregiver mental health data lead to expanded support programs or labeling considerations for holistic patient care?
18
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
